Arzneiwerk AG VIDA (LTS:0NKY) Other Current Receivables: €0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0NKY Arzneiwerk AG VIDA LTS:0NKY
40 GF Score
Price €0.51
! 7 Warning Signs
View Full Analysis

What is Arzneiwerk AG VIDA Other Current Receivables?

Arzneiwerk AG VIDA LTS:0NKY 40 Other Current Receivables is €0.00 Mil as of Mar. 2026. GuruFocus rates LTS:0NKY with a GF Score™ of 40/100. The stock has 7 warning signs investors should review.

Arzneiwerk AG VIDA's Other Current Receivables for the quarter that ended in Mar. 2026 was €0.00 Mil.

Arzneiwerk AG VIDA's annual Other Current Receivables increased from Dec. 2023 (€0.02 Mil) to Dec. 2024 (€0.03 Mil) but then declined from Dec. 2024 (€0.03 Mil) to Dec. 2025 (€0.00 Mil).

Arzneiwerk AG VIDA Other Current Receivables Related Terms

Arzneiwerk AG VIDA Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Arzneiwerk AG VIDA's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arzneiwerk AG VIDA Other Current Receivables Chart

Arzneiwerk AG VIDA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.05 0.11 0.02 0.03 0.00

Arzneiwerk AG VIDA Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
LTS:0NKY
40GF Score
Arzneiwerk AG VIDA LTS:0NKY
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Arzneiwerk AG VIDA Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of €0.00 Mil mean?
Arzneiwerk AG VIDA (LTS:0NKY) has a Other Current Receivables of €0.00 Mil as of Mar. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Arzneiwerk AG VIDA and its competitors.
Is Arzneiwerk AG VIDA's Other Current Receivables too high?
Arzneiwerk AG VIDA's current Other Current Receivables is €0.00 Mil. Overall, Arzneiwerk AG VIDA has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does Arzneiwerk AG VIDA's Other Current Receivables compare to MCK and COR?
Arzneiwerk AG VIDA's Other Current Receivables of €0.00 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Medical Distribution company?
A good Other Current Receivables depends on the Medical Distribution industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Arzneiwerk AG VIDA and its competitors. Arzneiwerk AG VIDA's current Other Current Receivables is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arzneiwerk AG VIDA stock overvalued right now?
Arzneiwerk AG VIDA (LTS:0NKY) has a current Other Current Receivables of €0.00 Mil. The current Other Current Receivables is €0.00 Mil. Arzneiwerk AG VIDA's overall GF Score™ is 40/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Arzneiwerk AG VIDA (LTS:0NKY), the current Other Current Receivables is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Arzneiwerk AG VIDA Business Description

Other Exchanges TLIK:Germany
Address Ordensmeisterstrasse 15-16, Berlin, DEU, 12099
Arzneiwerk AG VIDA is active in the pharmaceutical industry. The Pharma segment combines pharmaceutical supply with a focus on digitalization and process optimization along the pharmaceutical value chains and the management of large data volumes in the pharmaceutical industry. The company focuses on the growth area of specialty pharma in Germany and Europe.
40GF Score

Get the complete analysis for LTS:0NKY

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.51
Price